Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
- PMID: 32675217
- PMCID: PMC7476272
- DOI: 10.1136/heartjnl-2020-317355
Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
Abstract
Objective: To assess the prevalence, characteristics and prognostic value of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in hospitalised, non-intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19).
Methods: This single-centre, observational, cross-sectional study included 211 patients with COVID-19 admitted to non-ICU departments who underwent a single transthoracic echocardiography (TTE). Patients with poor acoustic window (n=11) were excluded. Clinical, imaging, laboratory and TTE findings were compared in patients with versus without PH (estimated systolic pulmonary artery pressure >35 mm Hg) and with versus without RVD (tricuspid annular plane systolic excursion <17 mm or S wave <9.5 cm/s). The primary endpoint was in-hospital death or ICU admission.
Results: A total of 200 patients were included in the final analysis (median age 62 (IQR 52-74) years, 65.5% men). The prevalence of PH and RVD was 12.0% (24/200) and 14.5% (29/200), respectively. Patients with PH were older and had a higher burden of pre-existing cardiac comorbidities and signs of more severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (radiological lung involvement, laboratory findings and oxygenation status) compared with those without PH. Conversely, patients with RVD had a higher burden of pre-existing cardiac comorbidities but no evidence of more severe SARS-CoV-2 infection compared with those without RVD. The presence of PH was associated with a higher rate of in-hospital death or ICU admission (41.7 vs 8.5%, p<0.001), while the presence of RVD was not (17.2 vs 11.7%, p=0.404).
Conclusions: Among hospitalised non-ICU patients with COVID-19, PH (and not RVD) was associated with signs of more severe COVID-19 and with worse in-hospital clinical outcome.
Trial registration number: NCT04318366.
Keywords: echocardiography; pulmonary vascular disease.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures

Comment in
-
Integrated clinical role of echocardiography in patients with COVID-19.Heart. 2020 Dec;106(23):1864-1865. doi: 10.1136/heartjnl-2020-318310. Epub 2020 Oct 14. Heart. 2020. PMID: 33055151 No abstract available.
-
Integrated clinical role of echocardiography in patients with COVID-19 disease.Heart. 2020 Dec;106(23):1864. doi: 10.1136/heartjnl-2020-318309. Epub 2020 Oct 14. Heart. 2020. PMID: 33055152 No abstract available.
References
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous